Bi Profenid LP is generally used for managing symptoms related to inflammatory or irritative states across conditions involving physical discomfort. Its use is focused on easing the symptom burden in clinical settings marked by heightened patient distress or functional interference, and may assist with maintaining comfort and stability.

This medication is indicated for use in a range of symptom-driven conditions, including those characterized by chronic inflammatory rheumatisms like rheumatoid arthritis and severe osteoarthritis, as well as acute issues such as sciatica, lumbago, and soft-tissue inflammation like tendonitis. It is applied to help manage symptoms when they become more disruptive during acute inflammatory flares (e.g., gout).

This medication may be applied across domains where additional symptomatic support is needed for conditions involving acute or fluctuating symptom patterns. The prolonged-release nature of the formulation is intended to provide supportive relief that helps maintain comfort more steadily with both long-term and episodic manifestations, and contributes to maintaining a sense of stability when symptoms are more noticeable during symptomatic periods.

---

Quick Fact: Relief for Inflammatory Discomfort

(This formulation helps to address clusters of symptoms that interfere with daily comfort, particularly pain and stiffness associated with chronic joint conditions, and is relevant when supportive symptom management is appropriate.)

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Rules for Bi Profenid LP

Bi Profenid LP (Ketoprofen prolonged-release) is generally approved for use in adults (typically age 18 and older), though some international labels permit use for adolescents starting at age 15. The safety and effectiveness of this formulation have not been established in pediatric patients (below 18 years of age) according to regulatory labeling.

---

Populations for Whom Use is Contraindicated

Use of this medicine is strictly prohibited (contraindicated) for patients with the following conditions, as stated in regulatory documents:

• Known Hypersensitivity to ketoprofen, or a history of allergic reactions, asthma, or urticaria triggered by aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
• Active Gastrointestinal Disease, including peptic ulcer, or a history of gastrointestinal bleeding or perforation.
• Severe Organ Impairment: Patients with severe hepatic insufficiency, severe renal insufficiency, or severe heart failure.
• Cardiovascular Surgery: Management of pain right before or after Coronary Artery Bypass Graft (CABG) surgery.

---

Restricted and Conditional Use

• Pregnancy: The medicine is contraindicated from 30 weeks of gestation onward (third trimester). Use between 20 and 30 weeks is generally discouraged unless medically necessary.
• Lactation: Use is not recommended due to insufficient data on infant risk.
• Geriatric Patients: Older adults (ge 65 years) are at a higher risk for serious adverse effects and should be monitored closely, often requiring the use of the lowest effective dose.
• Organ Impairment: Patients with mild-to-moderate renal or hepatic impairment require careful monitoring and may need specific dosage restrictions, as defined by official labeling.

Interactions with other medicines and products

The interaction profile for Ketoprofen (Bi Profenid LP) is primarily defined by additive safety risks and altered clearance of co-administered medicinal products, as detailed in regulatory documents.

Documented Interaction Patterns

The official label states specific restrictions and required monitoring for combinations falling into two main categories:

1. Pharmacodynamic (Additive Risk) Interactions:

• Other NSAIDs and High-Dose Salicylates: Co-administration is formally restricted due to the combined, increased risk of gastrointestinal ulceration and bleeding.
• Anticoagulants, Antiplatelet Agents, and SSRIs: These combinations increase the overall risk of hemorrhage and bleeding events.
• Diuretics, ACE Inhibitors, and ARBs: Combining these may diminish the antihypertensive or diuretic effect and elevate the risk of acute renal dysfunction.

2. Pharmacokinetic (Altered Clearance) Interactions:

• Lithium and Methotrexate (ge 15 mg/week): Ketoprofen's presence officially reduces the renal clearance of these medicines, leading to an increase in their plasma concentrations and heightened potential for toxicity. The combination with Probenecid is not recommended as it significantly reduces Ketoprofen clearance.

Interactions with Food and Substances

Co-administration with alcohol increases the risk of gastrointestinal bleeding. For the prolonged-release tablet, taking it with a high-fat meal may result in a slowing of the absorption rate.

How Bi Profenid LP Works

---

The mechanism centers on the non-selective inhibition of the Cyclooxygenase ( COX) enzymes, specifically both the constitutive COX-1 and the inducible COX-2 isoforms. This molecular interaction prevents the conversion of arachidonic acid into prostaglandins ( PGs), signaling molecules involved in nociception and local physiological response . A secondary mechanism involves inhibiting the Lipoxygenase ( LOX) pathway and antagonizing bradykinin, which also modulate the cascade of pro-inflammatory signals, thereby defining the drug's pharmacodynamic consequence.

By reducing PG levels, the drug modulates the nociceptive signaling pathway, diminishing the electrical sensitivity of peripheral nerve endings, which alters the stimulus required for signal transmission. The drug also crosses into the central nervous system (CNS), where it inhibits PGE2 synthesis in the hypothalamus. This central action modulates the body's core temperature set point, initiating physiological changes that govern heat dissipation.

Bi Profenid LP's dual-release mechanism provides rapid initial COX blockade, determining the speed of pathway modulation, and maintains a necessary drug concentration for prolonged enzyme engagement, achieving sustained modulation of signaling pathways over an extended duration.

How to Use Bi Profenid LP

The administration of Bi Profenid LP, a prolonged-release formulation of ketoprofen, follows standard protocols for oral NSAID therapy, focusing on correct form handling, frequency, and dosage limits.

---

Administration Method and Frequency

This medication is administered via the oral route. Due to its specific design as a prolonged-release (LP) tablet, the standard administration pattern is once per day (qDay), which utilizes the controlled release mechanism to maintain sustained levels of the active ingredient.

Procedural Requirements

The tablet must be swallowed whole with a glass of water. It is essential not to cut, crush, or chew the prolonged-release tablet, as this action would compromise the integrity of the controlled-release system, leading to rapid drug release and unintended dosing. The dose can be taken with or without food, though taking it with food, milk, or an antacid may help mitigate common gastrointestinal discomfort.

---

Official Dosing Parameters

The standard clinical approach is that the dose should utilize the lowest effective dose for the shortest possible duration necessary to achieve symptomatic relief. For adults, the typical daily dosing range is 100 mg to 200 mg. The maximum recommended total daily dose for the prolonged-release formulation is 200 mg.

Population-Specific Guidelines

Specific adjustments to the standard regimen are indicated for certain patient populations. Older adults (such as the very elderly) typically begin treatment with a reduced initial dose. Dose reduction is also utilized for individuals with impaired renal or hepatic function, often limiting the maximum daily intake to 150 mg or 100 mg, depending on the severity of impairment.

Recent Clinical Evidence Overview

Research on Compound Activity

Studies have investigated the theoretical framework of the compound's activity. The formulation, which features both an immediate and slow-release component of ketoprofen, is designed to influence the drug's absorption profile.

---

Studies in Musculoskeletal Conditions

Clinical trials have examined the compound in patients experiencing acute pain associated with rheumatologic or traumatic pathologies. Researchers have investigated changes in joint function parameters and reported pain levels in conditions such as osteoarthritis, rheumatoid arthritis, and acute low back pain. In some large-scale, real-world observational studies, the compound was frequently prescribed for these acute episodes.

---

Comparative Research

Some research has included comparisons of the modified-release ketoprofen formulation to immediate-release formulations in patients with inflammatory joint diseases. These double-blind comparative studies found that the different formulations resulted in comparable effects on measures such as pain intensity and morning stiffness. A number of studies have also focused on whether different dosage regimens of the modified-release formulation show non-inferiority to one another in managing pain related to acute trauma and rheumatologic conditions.

---

Adverse Events and Dosing Research

Studies reported on the frequency of adverse events in adult participants, commonly focusing on reported adverse events at different dosage levels. Overall safety monitoring in post-marketing surveys has also been conducted to evaluate the general tolerance and reasons for discontinuing treatment in patients with chronic pain, such as that associated with osteoarthritis.

Key Studies & References

1. Efficacy and tolerability of controlled-release ketoprofen in patients with rheumatoid arthritis: A randomized, double-blind study

Common questions about Bi Profenid LP (FAQ)

---

Q: Do you feel the effects of Bi Profenid LP immediately?

Bi Profenid LP is a prolonged-release formulation, meaning the medicine is designed to be absorbed gradually. Official information for similar extended-release formulations suggests that the drug levels in the bloodstream start to increase approximately 2 to 3 hours after administration, with peak concentrations typically reached around 6 to 7 hours.

---

Q: How long does one dose of Bi Profenid LP usually last?

The prolonged-release (LP) formulation is designed to release the medicine gradually. Regulatory information describes its standard use as once daily, which aims to provide sustained therapeutic concentrations of the active ingredient for an extended duration.

---

Q: What happens if I forget to take a dose of Bi Profenid LP?

Information found in official patient guidance describes the general approach to a missed dose: if a dose is forgotten, it is typically suggested to take it as soon as possible, unless the next dose is due shortly. If close to the next scheduled dose, the advice is generally to omit the forgotten dose and continue the regular schedule. Official guidance cautions against taking a double dose.

---

Q: Can Bi Profenid LP be taken at the same time as paracetamol (acetaminophen)?

Official interaction checks often show no known interactions between the active ingredient, ketoprofen, and paracetamol (acetaminophen). However, individuals should seek information from their healthcare professional regarding all medicine combinations, as this does not mean no interactions exist.

---

Q: Are there any age restrictions for taking Bi Profenid LP?

The safety and effectiveness of this specific prolonged-release formulation have generally not been established in children. Use is most commonly approved for adults, typically age 18 and older, although some international regulatory labels may permit its use for adolescents beginning at age 15.

---

Q: Is Bi Profenid LP generally suitable for older adults?

Official eligibility rules indicate that older adults (geriatric patients) have a higher risk for serious side effects, such as gastrointestinal bleeding. Regulatory documents describe that this population may require close monitoring and often involves using the lowest effective dose for the shortest duration.

---

Q: Is there a concern about Bi Profenid LP interacting with alcohol?

Yes, official safety information highlights a concern regarding this combination. Co-administration of the medicine with alcohol is noted to increase the risk of gastrointestinal bleeding.

---

Q: Does Bi Profenid LP interact with any common over-the-counter medicines?

Official labeling requires caution when combining this medicine with other common over-the-counter drugs that are also classified as NSAIDs or that contain salicylates (like aspirin). This combination can raise the overall risk of serious adverse events, particularly gastrointestinal bleeding.

---

Q: Does Bi Profenid LP contain an opiate?

No. Bi Profenid LP contains the active ingredient ketoprofen, and it is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification confirms it is a non-narcotic agent used for pain and inflammation.

---

Q: Is Bi Profenid LP available without a prescription?

The prolonged-release formulation of this medicine, containing the prescribed strength of ketoprofen, is typically classified as a prescription-only medicine in most countries where it is regulated.

---

Q: Are there generic versions of Bi Profenid LP?

Yes. The active ingredient, ketoprofen, is available in the marketplace as a generic formulation of the extended-release product, following the expiration of the relevant patents.

---

Q: Is it true that Bi Profenid LP can affect the kidneys?

Yes. Regulatory documents state that potential adverse reactions include impairment of renal function and, less commonly, renal failure, particularly in individuals with pre-existing kidney risk factors or those who use the medicine for extended periods.

---

Q: Can Bi Profenid LP affect blood pressure?

Official safety labeling lists hypertension (high blood pressure) as a possible adverse reaction. The class of medicines to which Bi Profenid LP belongs (NSAIDs) is generally associated with the risk of new-onset or worsening of existing high blood pressure.

---

Q: Can Bi Profenid LP cause liver problems?

Yes. While less common, regulatory documents have reported adverse reactions related to the liver, including hepatic dysfunction, hepatitis, and jaundice. Individuals with pre-existing liver issues are at a higher risk.

---

Q: Can Bi Profenid LP cause issues with sleeping?

Official documents describe that the medicine can affect the central nervous system, and these effects can include both somnolence (drowsiness or feeling sleepy) and insomnia (difficulty falling asleep or staying asleep).

---

Q: Is it necessary to have regular medical checks while taking Bi Profenid LP?

Official safety information for individuals using this medicine for an extended duration describes that monitoring may be advised. This monitoring may involve regular testing, such as blood work, to assess the function of organs like the kidneys and liver, and to check blood pressure.

---

Q: Is it normal to notice undigested parts of the tablet in stool?

Some prolonged-release tablets are manufactured with an outer matrix designed to pass through the digestive tract largely unchanged after the active medicine has been released. If this occurs, it may be a characteristic of some sustained-release systems, and the passing of the empty shell does not necessarily indicate a failure of the dose.

---

Q: Does Bi Profenid LP have a ceiling effect for pain relief?

Official information for the immediate-release formulation of the active ingredient indicates that doses beyond a certain threshold are not likely to provide greater relief. This suggests that a maximum effective dose, or 'ceiling effect,' is associated with this medication.

---

Q: Can Bi Profenid LP be used for headaches?

Bi Profenid LP is formally indicated for the symptomatic relief of pain, fever, and inflammation associated with various conditions. While headache is a pain symptom, its formal labeling does not specifically list headache treatment, though the active ingredient may be prescribed for this purpose.

---

Q: Why is ketoprofen, the active ingredient, sometimes classified differently than other NSAIDs?

Official descriptions of its mechanism indicate that in addition to the standard NSAID action of inhibiting the COX enzymes, ketoprofen is also described to inhibit the Lipoxygenase ( LOX) pathway and antagonize bradykinin. This additional action is what can differentiate its full pharmacological profile from some other NSAIDs.

---

Q: Do regulatory bodies classify Bi Profenid LP as having a high risk?

The medicine is required by regulatory bodies to carry serious warnings (sometimes known as 'Black Box' warnings) regarding the potential for major adverse events. These include life-threatening risks of gastrointestinal bleeding/ulceration and serious cardiovascular thrombotic events such as heart attack or stroke.

---

Q: Are there any dietary restrictions mentioned in the official information for Bi Profenid LP?

Official interaction information notes that taking the prolonged-release tablet with a high-fat meal may result in a slowing of the absorption rate of the active medicine. No specific food groups are generally restricted.

Official Storage and Disposal Instructions

Storage and disposal requirements for Bi Profenid LP (ketoprofen prolonged-release) are mandated by regulatory authorities to ensure product quality.

---

Storage Requirements

• Store at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F).
• The medication must be kept from freezing and protected from excess heat and moisture.
• Store the product in its original container, ensuring it is tightly closed and protected from light.
• The medication must be kept out of the sight and reach of children, with safety caps locked.

---

Disposal Protocols

• Do not flush the medication down the toilet or pour it into a drain.
• Dispose of all unused or expired product via a drug take-back program or as directed by local regulations.